Key statistics
On Thursday, Halozyme Therapeutics Inc (RV7:FRA) closed at 56.28, -3.27% below its 52-week high of 58.18, set on Aug 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 55.72 |
---|---|
High | 56.28 |
Low | 55.72 |
Bid | 56.08 |
Offer | 56.48 |
Previous close | 56.30 |
Average volume | 1.25k |
---|---|
Shares outstanding | 123.15m |
Free float | 121.91m |
P/E (TTM) | 17.74 |
Market cap | 7.50bn USD |
EPS (TTM) | 3.43 USD |
Data delayed at least 15 minutes, as of Mar 13 2025 15:44 BST.
More ▼
Press releases
- Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
- HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS
- Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results
- CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
- Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
- Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
- Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
- Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
- Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications
More ▼